Objective: To investigate the effect of dexmedetomidine combined with different doses of midazolam on hemodynamics, postoperative inflammatory mediators and cognitive function in patients with non-small cell lung cancer (NSCLC). Methods: NSCLC patients (n=120) who came to the First Affiliated Hospital of Zhengzhou University for surgical treatment from January 2019 to February 2021 were included and divided into low-dose group (n=60) and high-dose group according to different anesthesia regimens Group (n=60), both groups were given dexmedetomidine, on this basis, the low-dose group was given 0.05 mg/kg midazolam, and the high-dose group was given 0.10 mg/kg midazolam. The hemodynamics, inflammatory mediators, cognitive function, recovery quality and incidence of adverse reactions were compared between the two groups. Results: The heart rate (HR) and mean arterial pressure (MAP) increased and then decreased at the time points from 10 minutes after induction of anesthesia (T1) to 5 minutes after extubation (T3) in the two groups, and immediately after extubation (T2) and T3 time points The high-dose group was lower than the low-dose group (P<0.05). The visual analogue scale (VAS) score of pain after awakening in the high-dose group was lower than that in the low-dose group, and the eye opening time, extubation time, and anesthesia recovery room (PACU) stay time were all shorter than those in the low-dose group (P<0.05). The levels of interleukin-1 (IL-1), C-reactive protein (CRP), and tumor necrosis factor-α (TNF-α) in the two groups increased before operation, 3 days after operation, and 7 days after operation, and then decreased, and 3 days after operation., 7 days after operation in the high-dose group was lower than that in the low-dose group (P<0.05). There was no significant difference in the Mini Mental State Scale (MMSE) scores between the two groups at 1 day, 3 days and 7 days after operation (P>0.05). There was no statistical difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Compared with 0.05 mg/kg midazolam, dexmedetomidine combined with 0.10 mg/kg midazolam in patients with NSCLC surgery can maintain hemodynamic stability, improve the quality of recovery, and reduce inflammatory stress. The effect is more significant, and it does not increase the incidence of cognitive impairment and adverse reactions. [ABSTRACT FROM AUTHOR]